Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:10:48 EDT Mon 21 Apr 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:AZN - ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS - https://www.astrazeneca.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AZN - Q0.567.05·80.001.367.59+0.540.83,796.167.145  68.15  67.0987.67  61.24Apr 17Mar 3115 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-31 12:00U:AZNNews ReleaseAZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
2025-03-31 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
2025-03-25 19:02U:AZNNews ReleaseNew study results reinforce TAGRISSO(TM) (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
2025-03-14 12:00U:AZNNews ReleaseAstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
2025-03-07 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
2025-03-01 17:30U:AZNNews ReleasePositive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
2025-02-26 07:00U:AZNNews ReleaseCamizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
2025-02-14 11:10U:AZNNews ReleaseIMFINZI(TM) (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
2025-02-06 07:00U:AZNNews ReleaseAstraZeneca's Full Year and Q4 2024 results
2025-01-27 18:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
2025-01-23 14:31U:AZNNews ReleaseAstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery
2025-01-22 08:30U:AZNNews ReleaseDemand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
2025-01-17 17:35U:AZNNews ReleaseDATROWAY(TM) (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
2025-01-17 07:00U:AZNNews ReleaseCALQUENCE(TM) (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
2025-01-13 07:00U:AZNNews ReleaseDatopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2024-12-26 09:00U:AZNNews ReleaseAchievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
2024-12-18 09:05U:AZNNews ReleaseAlexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform
2024-12-11 10:15U:AZNNews ReleaseLYNPARZA(TM) (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
2024-12-09 07:00U:AZNNews ReleaseDatopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2024-12-08 11:00U:AZNNews ReleaseFixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial